JP2023549196A5 - - Google Patents
Info
- Publication number
- JP2023549196A5 JP2023549196A5 JP2023528189A JP2023528189A JP2023549196A5 JP 2023549196 A5 JP2023549196 A5 JP 2023549196A5 JP 2023528189 A JP2023528189 A JP 2023528189A JP 2023528189 A JP2023528189 A JP 2023528189A JP 2023549196 A5 JP2023549196 A5 JP 2023549196A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112523P | 2020-11-11 | 2020-11-11 | |
| US63/112,523 | 2020-11-11 | ||
| US202163151423P | 2021-02-19 | 2021-02-19 | |
| US63/151,423 | 2021-02-19 | ||
| PCT/EP2021/081304 WO2022101303A1 (en) | 2020-11-11 | 2021-11-10 | Methods of administering relugolix |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549196A JP2023549196A (ja) | 2023-11-22 |
| JPWO2022101303A5 JPWO2022101303A5 (https=) | 2024-11-15 |
| JP2023549196A5 true JP2023549196A5 (https=) | 2024-11-15 |
Family
ID=78709420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528189A Pending JP2023549196A (ja) | 2020-11-11 | 2021-11-10 | レルゴリクスの投与方法 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4243829A1 (https=) |
| JP (1) | JP2023549196A (https=) |
| WO (1) | WO2022101303A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7300935B2 (en) | 2003-01-29 | 2007-11-27 | Takeda Pharmaceutical Company | Thienopyrimidine compounds and use thereof |
| AR092707A1 (es) | 2012-09-28 | 2015-04-29 | Takeda Pharmaceuticals Co | Metodo de produccion de derivado de tienopirimidina |
| TWI744224B (zh) | 2015-02-26 | 2021-11-01 | 日商武田藥品工業股份有限公司 | 固形製劑 |
| AU2016317955B2 (en) * | 2015-09-01 | 2021-05-20 | Abbvie Inc. | Methods of administering Elagolix |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| MA46361A (fr) * | 2016-09-30 | 2021-03-31 | Myovant Sciences Gmbh | Traitement du cancer de la prostate |
| EA201992612A1 (ru) * | 2017-06-05 | 2020-05-20 | Обсева С.А. | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза |
| US20190054088A1 (en) * | 2017-08-18 | 2019-02-21 | Abbvie Inc. | Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis |
| WO2021069700A1 (en) | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
-
2021
- 2021-11-10 WO PCT/EP2021/081304 patent/WO2022101303A1/en not_active Ceased
- 2021-11-10 EP EP21810968.4A patent/EP4243829A1/en not_active Withdrawn
- 2021-11-10 JP JP2023528189A patent/JP2023549196A/ja active Pending